December 18, 2009
Sepracor Gets Extended Patent For Lunesta
By Brandon Butler
Marlborough-based Sepracor Inc. has received an extension for its patent on the sleeping drug Lunesta.
The patent has been extended by more than two years. It is now set to expire in February 2014.
The company also announced that the exclusivity period for the drug could be extended another six months pending the results of pediatric studies for the drug.
Clinical trials looking into the use of Lunesta in children had been put on hold by the federal Food and Drug and Drug Administration. However, that hold was recently released and Sepracor is "in the process of determining the next steps for the trials," according to a press release.
Sepracor was recently acquired by Japan's Dainippon Sumitomo Pharma.
WBJ Web Partners
Most Recent
Most Recent
0 Comments